newsfilter
← Latest News
GlobeNewswire·

Allogene Therapeutics Announces November Investor Events Highlighting Q3 Results and Initial ALLO-329 Autoimmune Clinical Data

Q3 2026 Financial Results and Business Update Conference Call and Webcast Scheduled for November 5, 2026 at 2:00 p.m. PT/5:00 p.m. ETALLO-329 Autoimmune Disease Program Webinar Featuring Preliminary Safety and Efficacy